Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir + Sofosbuvir in children with genotype 1 chronic hepatitis C
jRCTs051180110Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ledipasvir and sofosbuvir in hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoints: HCV RNA negativity at 4 weeks, HCV RNA negativity at 12 weeks and 2 more. Started Sep 2016; status: completed.
02
Drugs
ledipasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on jRCTs051180110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180110.